The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
May 17, 2024
View Complete Issue         Table of Contents 2019 
Ryzneuta for Prevention of Febrile Neutropenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ryzneuta for Prevention of Febrile Neutropenia
May 17, 2024 (Issue: 5071)
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the incidence of infection, as manifested by...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ryzneuta for Prevention of Febrile Neutropenia
Article code: 5071a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.